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ABSTRACT
One hundred thirty-eight patients with hematologic malignancies received myeloablative T cell-depleted periph-
eral blood stem cell transplant (PBSCT) from anHLA-identical sibling donor. TheT cell dose was adjusted to 0.2-1
 105 CD3 cells/kg. The CD34 dose was 2.7-16 106/kg. Patients with acute graft-versus-host disease (GVHD)
grade<2 received 1 or 2 donor lymphocyte infusions of 107 CD3 cells/kg between days 45 and 100. Patients were
designated according to relapse probability as standard or high relapse risk (77 and 61, respectively). Overall survival
(OS), relapse-free survival, relapse, and transplant-related mortality (TRM) were 58%, 46%, 40%, and 20%,
respectively, after a median follow-up of 4 years. Fifty-three (39%) and 21 (15%) patients developed grade 2-4 and
3-4 acuteGVHD. Forty-two (36%) had limited and 29 (25%) had extensive chronicGVHD. Inmultivariate analysis,
disease risk was an independent factor for OS and relapse, day-30 lymphocyte count for OS and TRM, and chronic
GVHD for OS and relapse. PBSCT with early T cell add back leads to comparable rates of chronic GVHD
compared with T cell-replete PBSCT. However, this chronic GVHD after T cell add back is associated with less
mortality and retains a protective effect in terms of relapse, at least in the standard-risk patients.
© 2006 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
In the past decade, peripheral blood stem cell
ransplantation (PBSCT) has been increasingly used
s an alternative to bone marrow transplantation
BMT). One potential beneﬁt of PBSCT is the higher
D34 cell dose, about twice as high as that of marrow
1]. High stem cell doses are associated with less leu-
emic relapse, and lower relapse rates have been re-
orted in some comparisons of PBSCT with BMT
2,3]. However, PBSCT also confers a higher risk of
hronic graft-versus-host disease (GVHD) and possi- d
318ly acute GVHD [1]. This increased risk of GVHD
ay be attributable to the higher doses of T cells,
bout a log increase over BMT. It has long been
pparent that T cell depletion of BMT reduces the
ncidence and severity of GVHD [4,5] and transplant-
elated mortality (TRM). However, the increased risk
f leukemic relapse from a weaker graft-versus-leuke-
ia (GVL) effect usually results in disease-free sur-
ivals (DFSs) similar to those with BMT that are not
cell depleted (TCD) [6]. There has been relatively
ittle experience with TCD-PBSCT partly due to the
ifﬁculty of eliminating the larger numbers of T cells in
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T Cell Depleted PBSCT 1319BSCT compared with BMT. Given the differences in
he cellular composition of PBSCT and BMT, it thus
emains an open question as to whether outcome from
BSCT could be improved by T cell depletion.
To explore the potential beneﬁt of high CD34
ose PBSCT with controlled T cell dosing, we devel-
ped a protocol whereby a granulocyte colony-stim-
lating factor-mobilized PBSC product underwent a
-5 log reduction of T cells before infusion. The
ransplantation product contained a ﬁxed low T cell
ose and a relatively high CD34 cell dose. To mini-
ize GVHD but boost GVL effects, patients who had
ot developed GVHD in the ﬁrst 6-8 weeks after
ransplantation received donor lymphocyte infusions
DLIs) at 45-100 days after transplantation. We de-
cribe outcomes in 138 consecutive patients who un-
erwent such TCD-PBSCT and examine factors af-
ecting relapse and survival.
ETHODS
atients
Between 1997 and 2004, patients with hemato-
ogic malignancies were treated at the National Insti-
utes of Health with TCD-PBSCT derived from
LA-matched related donors, under consecutive pro-
ocols 97-H-0099, 99-H-0046, 02-H-0111, and 04-
-0112 approved by the National Heart, Lung and
lood Institute institutional review board (Table 1).
everal patients with HLA-mismatched related do-
ors were enrolled in these protocols but were ex-
luded from this analysis. Written informed consent
as obtained according to principles outlined in the
eclaration of Helsinki.
reparative Regimen and Immunosuppression
All patients were conditioned with total body ir-
adiation (TBI) and cyclophosphamide 120 mg/kg (60
g/kg per day on days 3 to 2). TBI was given
able 1. Protocol Descriptions and Outcomes
Cohort n
TBI
(cGy)
Flu
(125
mg/m2)
CD3
Dose
(105/kg)
CSA
Dose
DLI Dose
(107/kg pe
day)
45 60 100
1 35 1360 — 1 SD 1 5
2 22 1360 — 0.5 LD 1 5
3 26 1200 — 0.5 LD† 1 5
4 35 1200 Yes 0.2 LD† 1 2
5 21 1200 Yes 0.2 LD‡ 1
BI indicates total body irradiation; Flu, ﬂudarabine; CSA, cyclospo
LD, low dose (100-200 g/L); HR, high risk; OS, overall survi
Not given in patients with acute graft-versus-host disease grade 
Starting day before DLI.
Stopped from day 21 to 59 unless graft-versus-host disease de
Nonsigniﬁcant difference between cohorts (percentage listed is actuarialwice daily in 8 equal fractions of 150-170 cGy each,
rom day 7 to 4. The last 56 patients also received
udarabine 125 mg/m (25 mg/m daily on days 8 to
4) in an attempt to minimize graft rejection. Cyclo-
porine (CSA) was the sole agent used as GVHD
rophylaxis. In attempts to minimize the dose and
uration of immunosuppression, 3 different schedules
ere evaluated: CSA was started on day 4 (ﬁrst 3
ohorts), day 44 (fourth cohort), and day 6 (ﬁfth
ohort ) and tapered after day 180 unless chronic
VHD occurred. In addition, in the ﬁfth cohort, CSA
as suspended between days 21 and 59. The rationale
or modifying the CSA schedule and transplanted T
ell dose was to ﬁnd a way to reduce or avoid CSA
mmunosuppression after a TCD-PBSCT without
ausing severe acute GVHD immediately after trans-
lantation. Cohort 1 established that some patients
eveloped acute GVHD despite TCD to 1  105/kg
nd standard-dose CSA (target level, 200-400 g/L).
n cohorts 2 and 3 we tested the requirement for CSA
o prevent acute GVHD by using a lower transplant T
ell dose of 0.5  105/kg. CSA was reduced to a low
ose (target level, 100-200 g/L) in cohort 2 and was
ithheld until DLI in cohort 3. In cohort 3, 2 patients
emonstrated transplant rejection [7]. Therefore, it
as deemed necessary to include CSA in the peri-
ransplantation period. Thus in cohort 4, we reduced
he T cell dose further (to reduce the risk of acute
VHD) and administered low-dose CSA (to prevent
raft rejection). This resulted in less acute GVHD and
o graft failure. In cohort 5, we then tested the effect of
topping low-dose CSA on day 21 after transplantation.
Individual cohorts are presented in Table 1.
tem Cell and Lymphocyte Collection
Stem cells and lymphocytes were collected from
he donor in separate apheresis procedures by using a
S3000 Plus automated blood cell separator (Baxter
ealthcare, Deerﬁeld, Ill). Before stem cell mobiliza-
Outcomes, n (%)§
R OS RFS Relapse TRM
(47) 18 (53  9) 13 (38  8) 14 (48  10) 6 (20  7)
(55) 10 (45  11) 8 (36  10) 10 (53  12) 4 (21  9)
(35) 15 (58  10) 13 (50  10) 6 (29  10) 7 (27  9)
(31) 24 (66  9) 22 (61  9) 7 (22  7) 6 (21  8)
(62) 17 (78  10) 14 (63  11) 5 (26  10) 2 (13  9)
LI, donor lymphocyte infusion; SD, standard dose (200-400 g/L);
S, relapse-free survival; TRM, transplant-related mortality.
tients in ﬁrst chronic-phase-chronic myeloid leukemia (CP-CML).
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A. Montero et al.1320ion, mononuclear cells were collected by a single 10- to
5-L leukapheresis and cryopreserved in liquid nitrogen
n aliquots for future DLIs. Lymphocytes were usually
ollected from donors in a single apheresis of 10-15 L
nd cryopreserved in liquid nitrogen until use. Donors
hen received granulocyte colony-stimulating factor (ﬁl-
rastim, Amgen, Thousand Oaks, Calif), 10 g/kg per
ay subcutaneously for 6 days. On days 5 and 6, a 15- to
5-L leukapheresis was performed using the CS3000
lus to obtain peripheral blood stem cells. Prophylactic
alcium chloride infusions were routinely administered
o avoid citrate toxicity. The minimal target CD34 dose
fter TCD was 3  106/kg.
Cell Depletion
CD34 selection and TCD were performed by 1 of
selection methods. In the ﬁrst cohort of patients
protocol 97-H-0099), the Ceprate selection system
CellPro, Bothell, Wash), based on biotin-avidin im-
unoadsorption, was used. This process included an
nitial CD34 selection on the Ceprate SC column,
ollowed by a CD2 selection on a second column.
fter this method became unavailable, cell products
ere depleted of T cells with the Isolex 300i immu-
omagnetic cell selection system (Baxter Healthcare)
sing the program for simultaneous positive and neg-
tive selections. On the Isolex system, we used the
anufacturer’s antibody for positive selection of
D34 cells and a cocktail of 3 T cell-speciﬁc mono-
lonal antibodies (CD2, CD6, and CD7; a gift from
r Ronald Gress) for negative selection of T cells.
he ﬁnal T cell dose of the allograft was ﬁxed between
.2 and 1  105 CD3 cells/kg depending on the
rotocol (Table 1) by supplementing the ﬁnal product
ith T cells from the original unmanipulated periph-
ral blood stem cell component. TCD-PBSCT prod-
cts were infused into patients immediately or cryo-
reserved in a controlled-rate freezer and stored in
iquid nitrogen for subsequent thawing and infusion.
ost-transplantation Donor Lymphocyte Infusions
To prevent relapse and facilitate immune recon-
titution, 1 or 2 lymphocyte infusions were scheduled
etween days  45 and 100 or speciﬁcally on day
60 (Table 1), excluding patients receiving steroid
reatment for acute GVHD grade 2.
nfection Prophylaxis
Bactrim double strength, 3 times a week was given
or Pneumocystis prophylaxis after engraftment and
ontinued until immunosuppression was discontin-
ed. Patients received ﬂuconazole during the ﬁrst 100
ays and high-dose acyclovir, if the patient or donor
as seropositive for cytomegalovirus. Weekly cytomeg-
lovirus monitoring (initially using blood antigenemia
nd later by polymerase chain reaction) was used to Tonitor reactivation. Valganciclovir, ganciclovir, or fos-
arnet was used to treat cytomegalovirus reactivation.
efinitions
To evaluate factors that affect outcome, patients
ere assigned to 2 risk categories. Those with acute
eukemia in ﬁrst remission, chronic myeloid leukemia
CML) in ﬁrst chronic phase, and myelodysplastic syn-
rome with refractory anemia were designated standard
isk (SR). Patients with more advanced disease were
esignated as high risk (HR). Chronic phase CML was
istinguished from advanced phase (accelerated and blas-
ic phase) according to criteria from the International
one Marrow Transplantation Registry (IBMTR) [8].
atients with other diagnoses (multiple myeloma,
hronic lymphocytic leukemia, non-Hodgkin lym-
homa, and chronic myelomonocytic leukemia) were
ategorized as SR or HR depending on refractoriness to
rior chemotherapy or unfavorable cytogenetics. At day
30 after transplantation, the lymphocyte count (LC30,
eﬁned as absolute lymphocyte count on day 30 after
ransplantation) was recorded from the routine complete
lood cell count. Overall survival (OS) was deﬁned as
ime from transplantation until death from any cause.
RM was deﬁned as time from transplantation until
eath from infectious cause, graft failure, GVHD, or
econdary malignancies.
tatistical Methods
Summary statistics, such as proportions, means,
tandard deviations, 95% conﬁdence intervals, medi-
ns, and ranges, were used to describe patient charac-
eristics, pretransplantation variables, and post-trans-
lantation outcomes. Kaplan-Meier estimates and
ox proportional hazard models were used to estimate
he time-to-event distributions of OS, relapse, and
RM. Statistical associations between pretransplanta-
ion variables were investigated using correlation anal-
sis, including Pearson correlation coefﬁcients and
pearman rank correlation coefﬁcients, and multiple
egression analysis. Statistical tests were based on t
ests. Chi-square tests and F tests were used to eval-
ate the statistical signiﬁcance of covariates in multi-
le regression models or the Cox proportional hazard
odels. The Wald score and likelihood ratio tests
ere used to evaluate the ﬁtness of the Cox propor-
ional hazard models. Data analysis was performed
ith SPSS 13 for Windows (SPSS, Inc, Chicago, Ill).
ESULTS
Between 1997 and 2004, 148 patients were en-
olled. Ten were excluded from analysis because of
onor-recipient HLA mismatch. Distribution of pa-
ients by treatment cohorts is presented in Table 1.
here was no difference in proportions of HR versus
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T Cell Depleted PBSCT 1321R patients between cohorts nor did their outcome
iffer (Table 1). Characteristics of patients are pre-
ented in Table 2. Median dose of CD34 cells 
06/kg was 5.8 (range, 2.7-16). One hundred twelve
atients received DLI (1 DLI in 70, 2 DLIs in 42).
wenty six patients did not receive DLI.
ngraftment
Neutrophil recovery to 0.5  109/L was
chieved between days 10 and 18. Two patients had
rimary graft failure and died at days 103 and 222.
etails of the kinetics of myeloid and T cell engraft-
ent in a subset population of this study has previ-
usly been published [9].
raft-versus-Host Disease
Excluding the 2 patients with graft failure, 83
atients (61%) had 0 or grade 1 acute GVHD. Fre-
uencies of grade 2-4 and 3-4 GVHD were 53 (39%)
nd 21 (15%), respectively. Four patients with grade
-4 acute GVHD were refractory to treatment with
orticosteroids. Surprisingly, despite aggressive TCD,
5 patients (11% of all patients and 27% of patients
ith GVHD grade 2), including 3 of 4 steroid re-
ractory patients, developed GVHD grade 2 before
dministration of DLI and did not receive DLI. The
emaining 11 patients did not receive DLI because of
arly death (n  7) or because they had CML in
olecular remission (n  4). There was no difference
n the rate of acute GVHD between TBI doses of
360 and 1200 cGy. Chronic GVHD was analyzed in
16 patients surviving 150 days. The 150-day land-
ark, rather than the conventional 100-day landmark,
as chosen because most patients had an extended risk
able 2. Characteristics of Patients (n  138)
ge (y), median (range) 34 (10-56)
ale (%) 54
emale/male (%) 24
MV seropositivity (%) 80
tandard risk 77
AML CR1 17
ALL CR1 5
CML CP1 42
MDS RA 10
Other 3
igh risk 61
AML > CR1 21
ALL > CR1 16
CML AP, BP 12
MDS > RA 8
Other 4
MV indicates cytomegalovirus; AML, acute myeloid leukemia;
ALL, acute lymphoblastic leukemia; CML, chronic myeloid
leukemia; CR1, ﬁrst complete remission; CP1, ﬁrst chronic
phase; MDS, myelodysplastic syndrome; RA, refractory anemia;
AP, accelerated phase; BP, blastic phase.f acute GVHD from the delayed T cell add back. Of *16 patients at risk, 45 (39%), 42 (36%), and 29 (25%)
ad absent, limited, and extensive chronic GVHD,
espectively. Most chronic GVHD responded well to
regimen of alternate-day prednisone and CSA and
he disease persisted only in a minority of patients. As
consequence, there was no late TRM attributable to
hronic GVHD (Figure 1). Of the 26 patients who did
ot receive DLI, 11 survived beyond day 150, and 6
55%) developed chronic GVHD.
Forty-four of 68 patients with an LC30 above the
edian of 0.3  109/L and 28 of 68 patients with an
C30 below the median developed chronic GVHD
chi-square, 6.53; df, 1; P .006). The dose of CD34
ells was not correlated with development of acute
chi-square, 0.031; df, 1; P  .86) or chronic (chi-
quare, 0.46; df, 1; P  .49) GVHD. Other variables
hat did not correlate with the development of GVHD
ere age, entered as a categorical variable below or
bove the median, dose and timing of CSA, DLI
yes/no), female versus male sex, or use of ﬂudarabine.
ransplantation Outcome
Eighty four patients were alive after a median
ollow-up of 47 months (range, 8.5-99). Forty-two
atients relapsed at a median of 166 days after trans-
lantation (range, 29-1805). Fifty-four patients died,
ith leukemia relapse being the major cause of mor-
Figure 1. Outcomes after TCD-PBSCT.
able 3. Causes of Death after T Cell Depleted Peripheral Blood
llotransplantation
Causes of Death n (%)
elapse 28 (20)
RM 25 (18)
Infection 8
GVHD/infection* 7
IPS/ARDS 6
Graft failure 2
Second graft failure 2
ccident 1
otal 54 (39)
RM indicates transplant-related mortality; GVHD, graft-versus-
host disease; IPS, idiopathic pneumonia syndrome; ARDS, acute
respiratory distress syndrome.After immunosuppression for GVHD.
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A. Montero et al.1322ality, followed by TRM (Table 3). Twenty-ﬁve pa-
ients died of TRM at a median of 108 days (range,
3-953), with only 1 patient dying1 year after trans-
lantation. Actuarial survival, relapse-free survival, re-
apse, and TRM were 58  5%, 46  5%, 40  5%,
nd 20  4%, respectively (Figure 1).
ariables Affecting Outcomes
Univariate analysis. Factors entered in univariate
nalysis for survival are listed in Table 4. Compared
ith those with SR disease, patients allocated to the
R category had worse survival (35% versus 76%;
 .0001) and DFS (28% versus 59%; P  .0001),
ore relapse (58% versus 29%; P  .0001), and
igher incidence of TRM (28% versus 14%; P  .02).
atients with LC30 above the median had better sur-
ival (73% versus 44%; P  .0006) and DFS (63%
ersus 31%; P  .001), lower TRM (9% versus 32%;
 .0007; Figure 2), and a tendency toward a low
ncidence of relapse (30% versus 50%; P  .1). The
able 4. Univariate Analysis (Log Rank) of Factors Affecting
urvival
Variable
OS
% P
ge (median 34) 0.34
Below median 64  6
Above median 54  6
D34 dose (median 5.8  106/kg) 0.96
Below 57  7
Above 60  6
ender 0.83
Female (62) 58  7
Male (76) 59  6
onor-patient sex match 0.27
Female to male (33) 59  5
Others (105) 58  9
LI* (n) 0.65
1 (70) 54  10
2 (46) 46  9
SA dose (n) 0.18
Standard (34) 53  9
Low (22) 45  11
Late or interrupted (82) 65  6
cute GVHD (n) 0.94
Absent (64) 58  7
Present (74) 58  6
hronic GVHD† (n) <.0001
Absent (45) 46  9
Present (71) 83  5
isk status <.0001
Standard (77) 76  5
High (61) 35  7
C30 (median 609 000/L) .0006
Below 44  6
Above 73  6
S indicates overall survival; DLI, donor lymphocyte infusion;
CSA, cyclosporine; GVHD, graft-versus-host disease; LC30,
absolute lymphocyte count on day 30 after transplantation.
Patients without DLI or with CML are excluded.
dLandmark analysis for survivors beyond 150 days.resence of chronic GVHD was found to be strong
rognostic factor for survival and DFS, which was
learly related to decreased rates of relapse (Figure 3).
Multivariate analysis. Factors affecting outcomes
ith P .1 in the univariate analysis were entered into
multivariate analysis. Risk category, chronic GVHD,
igure 2. Patients with LC30 above the median had signiﬁcantly
etter survival and lower TRM.
igure 3. Landmark analysis of patients surviving beyond day
150. Chronic GVHD (cGVHD) exerts its beneﬁcial effects by
ecreasing the rate of relapse. A, OS; B, DFS.
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T Cell Depleted PBSCT 1323nd LC30 were independent factors affecting survival
nd DFS. However, only the presence of chronic
VHD and SR disease were independently associated
ith a reduction in disease relapse, and LC30 above the
edian and SR disease were independently associated
ith reduction in TRM (Table 5). In a landmark analysis
f patients who were alive and free of disease after 150
ays, disease risk no longer maintained signiﬁcance as an
ndependent factor affecting DFS.
Interrelation between variables. CD34 cell dose did
ot inﬂuence OS or chronic GVHD incidence. How-
ver, patients with a CD34 cell dose above the me-
ian had a higher likelihood of having an LC30 above
he median (chi-square, 6.5; df, 1; P  .017), and
atients with an LC30 above the median had more
hronic GVHD and better survival.
ISCUSSION
Although stem cell transplantation using myeloa-
lative TBI-based conditioning is an effective and
ime-tested transplantation technique for hematologic
alignancies [10], success is limited by GVHD and
elapse, especially in HR leukemias. For over a decade
e have sought to deﬁne the cellular components of
he transplantation and GVHD prophylaxis regimen
hat produce the best outcome after TBI-based my-
loablative stem cell transplantation. In a series of
ransplantation protocols using different TCD ap-
roaches, we identiﬁed CD34 cell doses 3  106/kg
s a critical factor for success [11,12]. We used
BSCT because of its potential to optimize transplan-
ation outcome through the high CD34 doses avail-
ble. Even after TCD, with the 2 apheresis collections
e were able to achieve a median target CD34 cell
ose identical to the dose range reported to provide a
easure of protection against relapse [12]. As better
epletion techniques became available, the transplan-
able 5. Multivariate Analysis: Factors Associated with
ransplantation Outcome
Outcome Variable RR 95% CI P
S cGVHD 5.6 2.8-11.1 <.0001
Median >LC30 2.2 1.2-4.0 .008
High risk 0.3 0.1-0.5 <.0001
elapse No cGVHD 4.6 2.3-9.0 <.0001
Standard risk 0.3 0.2-0.6 <.0001
RM Median <LC30 4.9 1.8-13.1 .002
Standard risk 0.4 0.2-0.9 .018
FS cGVHD 5.7 2.5-12.9 <.0001
High risk 0.3 0.1-0.6 .002
Median >LC30 3.5 1.5-8.0 .003
R indicates risk ratio; CI, conﬁdence interval; OS, overall survival;
cGVHD, chronic graft-versus-host disease; LC30, absolute
lymphocyte count on day 30 after transplantation; TRM, trans-
plant-related mortality; DFS, disease-free survival.ation T lymphocyte dose was progressively reduced. cowever, it is surprising that TCD was not effective
t reducing the incidence of acute or chronic GVHD.
ithout CSA after transplantation, a T cell dose of
 104/kg was associated with unacceptable rates of
cute GVHD before DLI [7]. In subsequent proto-
ols, the T cell dose was reduced to 2 104/kg, which
till caused acute GVHD before DLI, even in the
resence of CSA. Acute GVHD (grade 2) before
LI occurred mostly in cohort 5 patients (n  9)
hose CSA was stopped on day 21 despite the low
ransplanted T cell dose of 2  104/kg. Thus, the goal
f delivering a TCD-PBSCT without immunosup-
ression after transplantation has not been achieved
nd low-dose CSA remains an important component
f treatment after transplantation. These results sug-
est that PBSCT lymphocytes have a greater potential
o cause GVHD than those from bone marrow.
These protocols resulted in a total incidence of
imited and extensive chronic GVHD of around 65%,
hich is similar to that reported for unmanipulated
BSCT. However, the morbidity encountered in our
atients was low and no patient died of chronic
VHD or associated late effects of chronic GVHD.
his may have been attributable to the TCD and
upports our earlier observation that low T cell dose at
ransplantation and not the later DLI is the major
actor determining chronic GVHD disease and sever-
ty [13]. In this study, we showed that chronic GVHD
s a strong predictor of survival due mostly to the
ecreased risk of relapse, similar to that described in
nmanipulated PBSCT. Our results contrast with a
arge IBMTR study that did not show decreased re-
apse with the development of chronic GVHD in
CD-BMT [14]. The difference in outcomes be-
ween these 2 studies of TCD stem cell transplanta-
ion could be due to the use of DLI in our protocol.
ur study showed a higher incidence of chronic
VHD compared with that reported after BMT
1,15]. We changed the schedule of giving donor lym-
hocytes as a preemptive approach to preventing re-
apse. The delayed add back of lymphocytes to se-
ected patients without GVHD appeared to be safe
nd the overall mortality from acute GVHD or acute
VHD and infection was very low (n  7, or 5%),
ith 4 patients dying from GVHD before receiving
LI and 3 dying from GVHD after DLI. The design
f these trials limited our ability to determine if the
econd DLI was beneﬁcial: patients with CML in ﬁrst
hronic phase (ie, SR patients) were scheduled for a
ingle DLI, which may have biased the results of a
ingle DLI toward a better outcome. Even after ex-
luding patients with CML, any beneﬁt from the sec-
nd DLI was confounded by competing variables: (1)
ccurrence of acute GVHD grade2, which excluded
atients from receiving DLI; and (2) death before a
econd DLI. In several analyses, we did not identify a
lear beneﬁt from any particular strategy for delayed
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A. Montero et al.1324ymphocyte add back [11,13,16] and found that vari-
tions in the schedule and dose of donor lymphocytes
id not emerge as factors affecting outcome. Thus, the
ole of preemptive DLI remains unclear.
Overall, the outcomes for this transplantation ap-
roach were closely comparable to those achieved
ith myeloablative stem cell transplantation in similar
atient populations. As is generally observed, patients
ith advanced disease had a high risk of relapse and
ortality. However, patients with earlier stages of
eukemia had excellent outcomes, comparing favor-
bly to other PBSCT approaches.
The relatively large cohort and long median fol-
ow-up of 4 years allowed us to search for factors that
ffected outcome. After disease risk, chronic GVHD
as the most powerful determinant of survival, DFS,
nd relapse. Our results emphasize the importance of
hronic GVHD in sustaining a GVL effect, whereas
he low mortality in patients with chronic GVHD
ranslated into a survival advantage. Thus, it appears
hat the transplantation approach with TCD-PBSCT
chieved a compromise between the deleterious ef-
ects of chronic GVHD and its beneﬁcial antileukemic
ffect. However, it should be noted that patients with
R disease are more likely than those with SR disease
o relapse before the development of chronic GVHD
nd, as such, beneﬁt less from a protective effect of
hronic GVHD.
An important early predictor of TRM and survival
as the LC30. This observation extends our previous
nalysis and is consistent with other studies suggesting
hat early lymphocyte recovery is favorable for outcome
17,18]. In a previous study we showed that LC30 was an
ndependent prognostic factor for transplantation out-
ome in patients with CML [19], suggesting that it may
e possible to control lymphocyte recovery by optimiz-
ng CD34 dose. Reports on the prognostic value of
D34 cell dose on outcome differ. In a large IBMTR
nalysis in BMT and PBSCT, higher CD34 cell doses
ere associated with less treatment failure [20]. In con-
rast, Urbano-Ispizua et al [21] who studied PBSCT
ound that a higher CD34 dose was associated with
orse survival due to higher TRM. Several other reports
ave described the implications of CD34 cell dose on
cute and chronic GVHD, relapse, and survival in T cell
eplete or nonmyeloablative stem cell transplantation
10,22-25]. In our study, CD34 dose did not predict for
urvival, relapse, TRM, or rates of GVHD, perhaps
ecause the dose range fell within an optimum zone for
utcome, and cell doses universally exceeded a critical
inimum level.
In summary, our results emphasize the importance
f chronic GVHD for sustaining a GVL effect after
llogeneic stem cell transplantation and show that it is
ossible to design protocols that minimize morbidity
nd mortality from chronic GVHD. The relatively
avorable effect of chronic GVHD was probably dueo the relatively short duration and mild manifestation
f the disease even when extensive. It is disappointing,
owever, that patients with HR leukemia continue to
elapse despite chronic GVHD. Further, attempts
o intensify GVL effects have been thwarted by our
nability to safely eliminate immunosuppression after
ransplantation. Thus, further modiﬁcations to the
trategy of TCD-PBSCT appear unlikely to improve
he outcome for patients with HR leukemia.
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